These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2809276)

  • 1. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
    von Wussow P; Jakschies D; Freund M; Deicher H
    J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
    Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
    Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
    Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
    J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
    Oberg K; Alm GV
    J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
    Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
    Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
    Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
    Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
    Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
    Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
    Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
    Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
    Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
    Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.
    Nolte KU; Günther G; von Wussow P
    Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
    Spiegel RJ; Jacobs SL; Treuhaft MW
    J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.
    Michallet M; Maloisel F; Delain M; Hellmann A; Rosas A; Silver RT; Tendler C;
    Leukemia; 2004 Feb; 18(2):309-15. PubMed ID: 14671645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
    Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
    Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia.
    Von Wussow P; Hehlmann R; Hochhaus T; Jakschies D; Nolte KU; Prümmer O; Ansari H; Hasford J; Heimpel H; Deicher H
    J Interferon Res; 1994 Aug; 14(4):217-9. PubMed ID: 7822880
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
    Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
    Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
    Bekisz JB; zur Nedden DL; Enterline JC; Zoon KC
    J Interferon Res; 1989 Sep; 9 Suppl 1():S1-7. PubMed ID: 2809275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autoimmune phenomena during interferon-alpha therapy for hematopoietic disorders].
    Iguchi T; Nishimaki J; Kawakubo K; Shimamoto T; Iwase O; Suzuki A; Kuriyama Y; Ito Y; Tauchi T; Yaguchi M; Miyazawa K; Kimura Y; Ohyashiki K
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1911-6. PubMed ID: 14650958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
    Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
    J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence and decay of the human Mx homolog in cancer patients during and after interferon-alpha therapy.
    Jakschies D; Hochkeppel H; Horisberger M; Deicher H; von Wussow P
    J Biol Response Mod; 1990 Jun; 9(3):305-12. PubMed ID: 2380745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of recombinant human alpha-2b and gamma interferons on bone marrow megakaryocyte progenitors (CFU-Meg) from patients with chronic myelocytic leukemia].
    Tanabe Y; Dan K; Kuriya S; Nomura T
    Rinsho Ketsueki; 1989 Oct; 30(10):1800-5. PubMed ID: 2512397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.